SG11201900738YA - Gpr156 variants and uses thereof - Google Patents
Gpr156 variants and uses thereofInfo
- Publication number
- SG11201900738YA SG11201900738YA SG11201900738YA SG11201900738YA SG11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA SG 11201900738Y A SG11201900738Y A SG 11201900738YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- gpr156
- aspartic acid
- pct
- protein
- Prior art date
Links
- 101150071692 Gpr156 gene Proteins 0.000 title 1
- 101001039301 Homo sapiens Probable G-protein coupled receptor 156 Proteins 0.000 abstract 4
- 102100041015 Probable G-protein coupled receptor 156 Human genes 0.000 abstract 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
- 235000003704 aspartic acid Nutrition 0.000 abstract 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- 230000004075 alteration Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000003104 endogenous depression Diseases 0.000 abstract 2
- 208000024714 major depressive disease Diseases 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 101100505306 Homo sapiens GPR156 gene Proteins 0.000 abstract 1
- -1 cDNA Chemical class 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIP0 I PCT omit VIII °nolo omolom omoi ioo Imo (10) International Publication Number WO 2018/022967 Al (51) International Patent Classification: C07K 14/705 (2006.01) C12Q 1/68 (2006.01) (21) International Application Number: PCT/US2017/044321 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/367,973 28 July 2016 (28.07.2016) US (71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US). (72) Inventor: GONZAGA-JAUREGUI, Claudia; 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US). (74) Agent: LEGAARD, Paul K.; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, Penn- sylvania 19355 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 N (54) Title: GPR156 VARIANTS AND USES THEREOF N (57) : The disclosure provides nucleic acids, including cDNA, comprising alterations that encode aspartic acid at a position el corresponding to position 533 of the hu man G protein- coupled receptor 156 protein (GPR156). The disclosure also provides isolated and recombinant human GPR156 protein variants that comprise an aspartic acid at a position corresponding to position 533. The change to aspartic acid, and the gene encoding this change, associate with unipolar depression. The disclosure also provides methods for 1-1 © determining whether a subject has or has a risk of developing unipolar depression, based on the identification of such alterations in f'1 the gene (DNA or RNA) encoding GPR156.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367973P | 2016-07-28 | 2016-07-28 | |
| PCT/US2017/044321 WO2018022967A1 (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900738YA true SG11201900738YA (en) | 2019-02-27 |
Family
ID=59649989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900738YA SG11201900738YA (en) | 2016-07-28 | 2017-07-28 | Gpr156 variants and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10266582B2 (en) |
| EP (2) | EP4230648A3 (en) |
| JP (2) | JP2019527229A (en) |
| KR (2) | KR102661616B1 (en) |
| CN (1) | CN109563516B (en) |
| AU (1) | AU2017302611B2 (en) |
| CA (1) | CA3032124A1 (en) |
| DK (1) | DK3491014T3 (en) |
| IL (1) | IL264473A (en) |
| MX (1) | MX2019001084A (en) |
| SG (1) | SG11201900738YA (en) |
| WO (1) | WO2018022967A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266582B2 (en) * | 2016-07-28 | 2019-04-23 | Regeneron Pharmaceuticals, Inc. | GPR156 variants and uses thereof |
| JP7237064B2 (en) | 2017-09-06 | 2023-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Single immunoglobulin interleukin-1 receptor-related (SIGIRR) variants and uses thereof |
| MX2021008291A (en) | 2019-01-17 | 2021-08-05 | Regeneron Pharma | A rodent model of mood disorders. |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5294533A (en) | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5271941A (en) | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5786138A (en) | 1993-01-29 | 1998-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Hyperstabilizing antisense nucleic acid binding agents |
| WO1994029444A1 (en) | 1993-06-04 | 1994-12-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for treating kaposi's sarcoma with antisense oligonucleotides |
| US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
| US5641754A (en) | 1994-01-10 | 1997-06-24 | The Board Of Regents Of The University Of Nebraska | Antisense oligonucleotide compositions for selectively killing cancer cells |
| JPH10503934A (en) | 1994-08-09 | 1998-04-14 | ノバルティス アクチエンゲゼルシャフト | Antitumor antisense oligonucleotide |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5994320A (en) | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| IT1275862B1 (en) | 1995-03-03 | 1997-10-24 | Consiglio Nazionale Ricerche | ANTI-SENSE TRANSCRIPT ASSOCIATED WITH SOME TYPES OF TUMOR CELLS AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL IN DIAGNOSIS AND TREATMENT |
| US6040296A (en) | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| WO1997014709A1 (en) | 1995-10-13 | 1997-04-24 | F. Hoffmann-La Roche Ag | Antisense oligomers |
| KR19990071523A (en) | 1995-11-21 | 1999-09-27 | 해리 에이. 루스제 | Inhibition of tumor growth by antisense oligonucleotides against IL-8 and IL-8 receptors |
| EP1007655A1 (en) | 1996-02-15 | 2000-06-14 | National Institutes Of Health | Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
| US5955590A (en) | 1996-07-15 | 1999-09-21 | Worcester Foundation For Biomedical Research | Conjugates of minor groove DNA binders with antisense oligonucleotides |
| US6046004A (en) | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| JPH1142091A (en) | 1997-07-25 | 1999-02-16 | Toagosei Co Ltd | Anti-sense nucleic acid compound |
| US6046319A (en) | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6007995A (en) | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
| US6013522A (en) | 1999-02-23 | 2000-01-11 | Isis Pharmaceuticals Inc. | Antisense inhibition of human Smad1 expression |
| US6025198A (en) | 1999-06-25 | 2000-02-15 | Isis Pharmaceuticals Inc. | Antisense modulation of Ship-2 expression |
| AU6343400A (en) * | 1999-07-09 | 2001-01-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene |
| US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
| WO2001079230A2 (en) * | 2000-04-18 | 2001-10-25 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ugt1a1 gene |
| CA2498264A1 (en) * | 2002-09-09 | 2004-05-13 | Nura, Inc. | G protein coupled receptors and uses thereof |
| DE10334188B4 (en) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Use of rotigotine to treat depression |
| US7572792B2 (en) * | 2004-04-29 | 2009-08-11 | Merck & Co., Inc. | Azetidine glycine transporter inhibitors |
| EP2091556B1 (en) | 2006-11-15 | 2018-07-25 | Omeros Corporation | Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease |
| EA201492116A1 (en) * | 2012-05-16 | 2015-05-29 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF MECP2 |
| UA118014C2 (en) | 2012-05-25 | 2018-11-12 | Те Ріджентс Оф Те Юніверсіті Оф Каліфорнія | METHOD OF METHOD MODIFICATION |
| IL300199A (en) | 2012-12-06 | 2023-03-01 | Sigma Aldrich Co Llc | Crispr-based genome modification and regulation |
| US10266582B2 (en) | 2016-07-28 | 2019-04-23 | Regeneron Pharmaceuticals, Inc. | GPR156 variants and uses thereof |
-
2017
- 2017-07-28 US US15/662,689 patent/US10266582B2/en active Active
- 2017-07-28 EP EP23162215.0A patent/EP4230648A3/en active Pending
- 2017-07-28 DK DK17754224.8T patent/DK3491014T3/en active
- 2017-07-28 MX MX2019001084A patent/MX2019001084A/en unknown
- 2017-07-28 AU AU2017302611A patent/AU2017302611B2/en active Active
- 2017-07-28 WO PCT/US2017/044321 patent/WO2018022967A1/en unknown
- 2017-07-28 JP JP2019504021A patent/JP2019527229A/en active Pending
- 2017-07-28 KR KR1020197001965A patent/KR102661616B1/en active IP Right Grant
- 2017-07-28 CN CN201780048589.4A patent/CN109563516B/en active Active
- 2017-07-28 CA CA3032124A patent/CA3032124A1/en active Pending
- 2017-07-28 KR KR1020247005755A patent/KR20240027874A/en not_active Application Discontinuation
- 2017-07-28 EP EP17754224.8A patent/EP3491014B1/en active Active
- 2017-07-28 SG SG11201900738YA patent/SG11201900738YA/en unknown
-
2019
- 2019-01-27 IL IL264473A patent/IL264473A/en unknown
- 2019-03-15 US US16/354,563 patent/US10562953B2/en active Active
-
2020
- 2020-01-03 US US16/733,663 patent/US11155598B2/en active Active
-
2021
- 2021-09-23 US US17/483,047 patent/US20220073589A1/en active Pending
-
2023
- 2023-02-10 JP JP2023019464A patent/JP2023071704A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10562953B2 (en) | 2020-02-18 |
| DK3491014T3 (en) | 2023-05-30 |
| KR102661616B1 (en) | 2024-04-30 |
| WO2018022967A1 (en) | 2018-02-01 |
| CN109563516A (en) | 2019-04-02 |
| JP2023071704A (en) | 2023-05-23 |
| JP2019527229A (en) | 2019-09-26 |
| EP3491014A1 (en) | 2019-06-05 |
| CN109563516B (en) | 2023-10-27 |
| IL264473A (en) | 2019-02-28 |
| KR20240027874A (en) | 2024-03-04 |
| US20180030114A1 (en) | 2018-02-01 |
| US20220073589A1 (en) | 2022-03-10 |
| US20190202891A1 (en) | 2019-07-04 |
| US20200231651A1 (en) | 2020-07-23 |
| EP3491014B1 (en) | 2023-04-05 |
| AU2017302611A1 (en) | 2019-03-14 |
| US11155598B2 (en) | 2021-10-26 |
| CA3032124A1 (en) | 2018-02-01 |
| EP4230648A2 (en) | 2023-08-23 |
| US10266582B2 (en) | 2019-04-23 |
| EP4230648A3 (en) | 2023-10-18 |
| AU2017302611B2 (en) | 2021-12-09 |
| MX2019001084A (en) | 2019-06-10 |
| KR20190034532A (en) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809649WA (en) | Macromolecule analysis employing nucleic acid encoding | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201906735RA (en) | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201407789RA (en) | Humanized non-human animals with restricted immunoglobulin heavy chain loci | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201901790YA (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| SG11201807134RA (en) | Transposon system and methods of use | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201900573UA (en) | Methods of purifying fc-containing proteins |